Progression of structural neuropathology in preclinical Huntington's disease: A tensor based morphometry study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 5, 2005, Pages 650-655

  Kipps, C M ^a,b   Duggins, A J ^b   Mahant, N ^b   Gomes, L ^b   Ashburner, J ^c   McCusker, E A ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GLOBUS PALLIDUS; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; MALE; MESENCEPHALON; MORPHOMETRICS; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SUBSTANTIA NIGRA; WHITE MATTER;

EID: 17644369971     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.047993     Document Type: Article

References (42)

1. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003;302:830-4.
2. Kremer B. Clinical neurology of Huntington's disease. In: Bates G, Harper P, Jones L, eds. Huntington's disease. Oxford: Oxford University Press, 2002:28-61.
3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-83.
4. Gonzalez-Gonzalez MC, Trujillo MJ, Rodriguez DA, et al. Huntington disease-unaffected fetus diagnosed from maternal plasma using QF-PCR. Prenat Diagn 2003;23:232-4.
5. Guidelines for the molecular genetics predictive test in Huntington's disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Neurology 1994;44:1533-6.
6. McCusker E, Richards F, Sillence D, et al. Huntington's disease: neurological assessment of potential gene carriers presenting for predictive DNA testing. J Clin Neurosci 2000;7:38-41.
7. Kirkwood SC, Siemers E, Bond C, et al. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch Neurol 2000;57:1040-4.
8. Kirkwood SC, Siemers E, Stout JC, et al. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol 1999;56:563-8.
9. Smith MA, Brandt J, Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000;403:544-9.
10. Rothwell JC. Huntington's disease. A predictor of pathology. Nature 2000;403:495-6.
11. Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998;121:1329-41.
12. Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992;31:425-30.
13. Gomez-Tortosa E, MacDonald ME, Friend JC, et al. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol 2001;49:29-34.
14. Thieben MJ, Duggins AJ, Good CD, et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002;125:1815-28.
15. Dedeoglu A, Kubilus JK, Yang L, et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 2003;85:1359-07.
16. Chen M, Ona C, Li M, et al. Minocycline inhibits caspase-1 and caspase-2 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
17. Kieburtz K. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
18. Kassubek J, Juengling FD, Kioschies T, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004;75:213-20.
19. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-77.
20. Lange H, Thorner G, Hopf A, et al. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976;28:401-25.
21. Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 1988;85:5733-7.
22. Mann DM, Oliver R, Snowden JS. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathol (Berl) 1993;85:553-9.
23. Halliday GM, McRitchie DA, Macdonald V, et al. Regional specificity of brain atrophy in Huntington's disease. Exp Neurol 1998;154:663-72.
24. Roos RA, Pruyt JF, de Vries J, et al. Neuronal distribution in the putamen in Huntington's disease. J Neurol Neurosurg Psychiatry 1985;48:422-5.
25. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985;227:770-3.
26. de la Monte SM, Vonsattel JP, Richardson EP Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988;47:516-25.
27. Aylward EH, Anderson NB, Bylsma FW, et al. Frontal lobe volume in patients with Huntington's disease. Neurology 1998;50:252-8.
28. Harris GJ, Codori AM, Lewis RF, et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999;122:1667-78.
29. Aylward EH, Codori AM, Barta PE, et al. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53:1293-6.
30. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552-60.
31. Grafton ST, Mazziotta JC, Pahl JJ, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992;49:1161-7.
32. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
33. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-42.
34. Ashburner J, Andersson JL, Friston KJ. Image registration using a symmetric prior-in three dimensions. Hum Brain Mapp 2000;9:212-25.
35. Freeborough PA, Fox NC. Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images. J Comput Assist Tomogr 1998;22:838-43.
36. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000;11:805-21.
37. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995;54:105-20.
38. Albin RL. Selective neurodegeneration in Huntington's disease. Ann Neurol 1995;38:835-6.
39. Aylward EH, Brandt J, Codori AM, et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994;44:823-8.
40. Lasker AG, Zee DS. Ocular motor abnormalities in Huntington's disease. Vision Res 1997;37:3639-45.
41. Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002;58:695-701.
42. Jenkins BG, Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-65.